PACKAGE LEAFLET: INFORMATION FOR THE USER. Neophyr 225 ppm mol/mol medicinal gas, compressed

Similar documents
PACKAGE LEAFLET: INFORMATION FOR THE USER. Medical Oxygen/Carbon Dioxide Mixtures Oxygen, Carbon Dioxide, Medicinal gas, compressed

Medical oxygen/carbon dioxide mixtures

Compressed Medical Oxygen Medicinal gas, compressed

Liquid Medical Oxygen Medicinal gas, cryogenic Package Leaflet: Information for the User

PACKAGE LEAFLET: INFORMATION FOR THE USER. FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride)

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT. Medicinal Air, Air Liquide 100%, medicinal gas, compressed. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Medical Gas Data Sheet (MGDS) Medical helium. BOC: Living healthcare

Medical Gas Data Sheet (MGDS) Medical helium. BOC: Living healthcare

Package leaflet: Information to the user. Medicinsk Lustgas Air Liquide 100%, medicinal gas, liquefied. Nitrous oxide 100% (medicinal laughing gas)

SUMMARY OF PRODUCT CHARACTERISTICS. 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/He AGA 0.28%, 9.3% medicinal gas, compressed

PACKAGE LEAFLET: INFORMATION FOR THE USER. Lamisil 1 % cutaneous spray solution Terbinafine hydrochloride

Package leaflet: Information to the user. Kalinox 50 %/50 % medicinal gas, compressed. Nitrous oxide / Oxygen

Pressure Regulator. Instructions for Use

Package leaflet: Information for the user. Medicinal Oxygen Air Liquide 100%, Medicinal gas, compressed. Oxygen 100% (O 2 )

Lung Function medical gas mixture 1.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Exembol Multidose 100 mg/ml concentrate for solution for infusion. Argatroban Monohydrate

Package leaflet: Information for the user Livopan 50%/50 % medicinal gas, compressed. Nitrous oxide / Oxygen

LABELLING OF MEDICAL GAS CONTAINERS

MEDICAL GAS CYLINDERS COLOUR CODING TD 09/15/E

INOmax MATERIAL SAFETY DATA SHEET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Lung Function medical gas mixture 4.

Package leaflet: Information for the patient

Material Safety Data Sheet. Helmar Crystal Kote Picture Varnish Gloss

Oxygen Dialflow Meter. Instructions for Use

Medical gases and mixture. New horizons for human health

CYLINDER VALVE GUIDELINES TD 12/15/E

Safety Data Sheet. Nitrous oxide. Version : see paragraph 16 "OTHER INFORMATION" see paragraph 16 "OTHER INFORMATION"

Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

TENSOSPRAY MSDS No. 188

Pressure Regulators. Instructions for Use

On the Go with Oxygen

Public Assessment Report Scientific discussion. Lung test gas CO (He) AGA, 0.28%, inhalation gas, compressed (carbon monoxide, helium) SE/H/1154/01/MR

Material Safety Data Sheet. Helmar Crystal Kote Fixative

Oxygen Therapy. What tests can be done to determine the need for oxygen?

MATERIAL SAFETY DATA SHEET

BUTANE TS-MSDS 44 1 IDENTIFICATION OF THE SUBSTANCE & OF THE COMPANY / UNDERTAKING IDENTIFICATION OF THE SUBSTANCE OR PREPARATION:

SAFETY DATA SHEET according to EC directive 2001/58/EC ENERGY LINE PLASTIC PRIMER

0800 POISON A

Medical Gas Data Sheet (MGDS) Medical air. BOC: Living healthcare

Material Safety Data Sheet Aerosol Nuart Retouch Varnish IDENTIFICATION OF THE MATERIAL AND SUPPLIER HAZARDS IDENTIFICATION.

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET "READ AND UNDERSTAND MATERIAL SAFETY DATA SHEET BEFORE HANDLING OR DISPOSING OF PRODUCT"

SAFETY DATA SHEET Clinell Sporicidal Wipes According to Regulation (EU) No 453/2010

Material Safety Data Sheet. Aerosol Nuart Mat Spray

SAFETY DATA SHEET ENTONOX (GAS MIXTURE OF 50% NITROUS OXIDE + 50% OXYGEN)

Emergency Mobile Unit Medicinal gases everywhere, always on time

DOLPHIN DIESEL FUEL TREATMENT

Safety Data Sheet according to (EC) No 1907/ ISO

SAFETY DATA SHEET ADI-FLOW Dry

COMARK PROBE WIPES PW70T and PW200T MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET (91/155/EC) IDENTIFICATION OF THE SUBSTANCE /

SAFETY DATA SHEET Isopropyl Alcohol 70% Product Number: 32

SAFETY DATA SHEET POCKET ROCKET (9069)

SAFETY DATA SHEET. Section 1. Identification of the Preparation and Company Product name Coverstain

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)

Symptoms relating to use: Symptoms of over exposure to vapours are sore throat, cough, shortness of breath, headache.

Material Safety Data Sheet According to 91/155 EEC

SAFETY DATA SHEET. CARBON DIOXIDE in non-refillable gas cylinders

SAFETY DATA SHEET ZGB00QELC500NW ELECTRICAL CLEANER 500ML

SAFETY DATA SHEET 49N SYNTHETIC GLOBAL ATF Revision Date:

Patient Information for the: Humanitarian Device for use in the Control of Air Leaks

SAFETY DATA SHEET. breathing difficulties if inhaled. Suspected of damaging fertility or the unborn child.

Material Safety Data Sheet

BRITISH COMPRESSED GASES ASSOCIATION Registered office: 4a Mallard Way, Pride Park, Derby, UK. DE24 8GX Company Number: 71798, England

1. IDENTIFICATION OF THE SUBSTANCE / PREPARATION AND THE COMPANY TRENDICOTE, TRENDICOTE/60, & TRENDICOTE/15

Safety Data Sheet according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

Sika Technique Primer 206 G+P

PDF created with pdffactory Pro trial version SAFETY DATA SHEET

CSL Behring PACKAGE LEAFLET: INFORMATION FOR THE USER

Safety data sheet according to ISO SDS No. 010 b/ GB

Rodilon Professional Rodenticide None

SAFETY DATA SHEET TOKUSO RESIN HARDENER-Ⅱ

Safety Data Sheet according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830

PEUGEOT PROTECT Tyre & Trim Dressing. PEUGEOT PROTECT Tyre & Trim Dressing, 400ml

Sanding Sealer Revision Date: 23/05/2002

SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking. Section 2: Hazards identification

SAFETY DATA SHEET GAS MIXTURES ARGON 75% CARBON DIOXIDE 25%

Health Products Regulatory Authority

0800 POISON A

MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET according to EC directive 2001/58/EC DILUENTE AUTOREFINISH.SPEEDY

MATERIAL SAFETY DATA SHEET (conforming to E.E.C. directive 2001/58) DW DESCALER Date of print 13/07/15 date / revised : Page 1

SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking. Section 2: Hazards identification

The content of your gas cylinders. Pocket Safety Guide No. 1

Safety Data Sheet according to (EC) No 1907/2006

Safety Data Sheet according to (EC) No 1907/2006

SAFTETY DATA SHEET WINSOR & NEWTON ARTISTS WORKABLE FIXATIVE

Yates Australia, a division of DuluxGroup (Australia) Pty Ltd ABN:

Material Safety Data Sheet

0800 POISON

Emergency Tel.No. Please contact the regional HiMedia representation in your country

X BOND CONSTRUCTION ADHESIVE SEALANT

CATALOGUE OF EIGA MEDICAL GASES PUBLICATIONS

Murphy and Son Ltd SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking

SAFETY DATA SHEET SAS54 AIR DUSTER 500ML

SAFETY DATA SHEET. Section 1: Identification of the substance/mixture and of the company/undertaking. Section 2: Hazards identification

Micro Dial-Flowmeter. Instructions for Use

Transcription:

PIL p. 1/6 PACKAGE LEAFLET: INFORMATION FOR THE USER Nitric oxide 225 ppm, 450 ppm, 1000 ppm mol/mol Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.. In this leaflet: 1. What Neophyr is and what it is used for 2. What you need to know before you use Neophyr 3. How to use Neophyr 4. Possible side effects 5. How to store Neophyr 6. Contents of the pack and other information 1. WHAT NEOPHYR IS AND WHAT IT IS USED FOR Neophyr is a gas mixture for inhalation use. Neophyr is a medicinal gas, compressed, consisting of a mixture of gases that contains 225 ppm, 450 ppm or 1000 ppm mol/mol of nitric oxide. What are its uses? Neophyr must be administered exclusively by healthcare professionals and it is only for strict hospital use. Neophyr is indicated in the following conditions: newborn babies with lung failure associated with high blood pressure in the lungs, a condition known as hypoxic respiratory failure. When inhaled, this gas mixture can improve the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches your baby s blood. newborn babies, babies, children, teenagers 0-17 years and adults with high blood pressure in the lungs, connected with heart surgery. This gas mixture can improve heart function and increase the flow of blood through the lungs.

PIL p. 2/6 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NEOPHYR Do not use Neophyr - If you (as the patient) or your child (as the patient) are allergic (hypersensitive) to nitric oxide or any of the other ingredients of this medicine (listed in section 6). - If you have been told that you (as the patient) or your child (as the patient) have an abnormal circulation within the heart. - If you (as the patient) or your child (as the patient) have congenital or acquired deficiency of methemoglobin reductase (MetHb reductase) or glucose 6 phosphate dehydrogenase (G6PD). Warnings and precautions Talk to your doctor before using Neophyr. Inhaled nitric oxide may not always be effective and thus other therapies may be considered necessary for you or your child. Inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the dose of inhaled nitric oxide must be reduced. Nitric oxide may react with oxygen forming nitrogen dioxide that may cause airway irritation. Your or your child s doctor will undertake monitoring of nitrogen dioxide and in case of elevated values the Neophyr therapy will be adjusted, decreased accordingly. Inhaled nitric oxide may have a mild but influence on the platelets (components that help the blood to clot) of you or your child and any signs of bleeding and or haematoma should be observed. If you see any signs or symptoms that may be associated to bleeding you should directly inform the doctor. No effect of inhaled nitric has been documented in newborn babies with a malformation where the diaphragm is not fully complete, so called congenital diaphragmatic hernia. In newborn babies with special malformations of the heart, what doctors calls congenital heart defects inhaled nitric oxide may cause a worsening of the circulation. Children Neophyr should not be used in preterm baby < 34 weeks of gestational age. Other medicines and Neophyr The doctor will decide when to treat you or your child with Neophyr and with other medicines, and will carefully supervise the treatment. Tell your doctor if you (as the patient) or your child (as the patient) are taking, have recently taken or might take any other medicine. Some medicines can affect the ability of blood to carry oxygen. These include prilocaine (a local anaesthetic used for pain relief in association to minor painful procedures e.g. suturing, and minor surgical or diagnostic procedures) or glyceryl trinitrate (used to treat chest pain). Your doctor will take care to check that the blood can carry enough oxygen when you are taking these medicines.

PIL p. 3/6 Pregnancy, breast-feeding and fertility Neophyr should not be used during pregnancy unless clearly necessary, such as in situations of life support. Exposure to nitric oxide in humans during lactation should be avoided. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 3. HOW TO USE NEOPHYR Your doctor will decide the correct dose of Neophyr and will administer Neophyr to you or your child s lungs through a system designed for delivering this gas. This delivery system will ensure that the correct amount of nitric oxide is delivered by diluting Neophyr with an oxygen/air mixture immediately before giving it to you. For you or your child s safety, the delivery systems intended for administration of Neophyr are fitted with devices that constantly measure the amount of nitric oxide, oxygen and nitrogen dioxide (a chemical formed when nitric oxide and oxygen are mixed) being delivered to the lungs. Your doctor will decide how long you or your child should be treated with Neophyr. Neophyr is given in dose of 10 to 20 ppm, (maximal dose 20 ppm in children and 40 ppm in adults) parts per million of the gas that you or your child inhale. The lowest effective dose will be sought. Therapy is usually required for about 4 days in newborn infants with lung failure associated with high blood pressure in the lungs. In children and adults with high blood pressure in the lungs, connected with heart surgery, Neophyr is usually given for 24-48 hours. However, therapy with Neophyr may last longer. If you receive more Neophyr than you should Too much of inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the Neophyr dose will be decreased and the administration of medicines such as vitamin C, methylene blue, or eventually blood transfusion, in order to improve the oxygen carrying capacity, may be considered. If you stop receiving Neophyr Treatment with Neophyr should not be stopped suddenly. Low blood pressure or a rebound increase in pressure in the lungs has been known to occur if treatment with Neophyr is stopped suddenly without first lowering the dose. At the end of treatment, the doctor will slowly lower the amount of Neophyr being given to you or your child, so that the circulation in the lungs is able to adjust to oxygen/air without Neophyr. Thus it may take a day or two before you or your child is off Neophyr therapy. If you have any further questions on the use of this medicine ask your doctor or other healthcare professionals.

PIL p. 4/6 4. POSSIBLE SIDE EFFECTS Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will notice and closely monitor any side effects. It is not likely that you will experience these side effects yourself. Side effects that are very commonly seen (affects more than 1 user in 10) in association with Neophyr therapy include: Low platelet count, abnormally low potassium concentration in the blood (hypokalemia), low blood pressure, airless or collapsed lung, abnormally high amounts of bile pigment (bilirubin) in the blood. Side effects that may be seen but the frequency is not known (frequency cannot be estimated from the available data) are: Rebound high blood pressure in the lungs (increase in pulmonary artery pressure), and too low amount of oxygen in the blood (oxygen desaturation/hypoxemia) due to sudden withdrawal of the treatment, increase in methemoglobin, thus reduced oxygen carrying capacity. Accidental ambient air exposure to nitric oxide, e.g. leakage from equipment or cylinder may cause headache. You should directly inform the personnel if you experience headache while being in close proximity to your child receiving Neophyr. If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. If you have any further questions on the use of this product ask your doctor or other healthcare professionals. Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie e-mail: medsafety@hpra.ie By reporting side effects you can help provide more information on the safety of this medicine. 5. HOW TO STORE NEOPHYR Keep this medicine out of the sight and reach of children. Neophyr therapy should only be used and handled by hospital personnel.

PIL p. 5/6 Neophyr cylinders should be stored secured in order to avoid falling and thus potentially causing harm. Neophyr should be used and administered only by personnel specially trained in the use and handling of Neophyr. All regulations concerning handling of pressurised cylinders must be followed. Storage is supervised by specialists at the hospital. Gas cylinders are to be stored in well-ventilated rooms or in ventilated sheds where they are protected from rain and direct sunlight. The cylinders must be stored at a temperature between -10 and +50 C. Protect the cylinders from shocks, falls, oxidising and flammable materials, moisture, sources of heat or ignition. Storage in the pharmacy department The gas cylinders should be kept in a place designated exclusively for medicinal gas storage that is well ventilated, clean and under lock and key. This place should house a separate, special facility for the storage of nitric oxide gas cylinders. Storage in medical department The cylinder should be placed in an area with appropriate equipment to ensure that the cylinder is held vertically. When the cylinder is empty, do not dispose of it. Empty cylinders will be collected by the supplier. Do not use this medicine after the expiry date which is stated on the gas cylinder label. The expiry date refers to the last day of that month. 6. CONTENTS OF THE PACK AND OTHER INFORMATION What Neophyr contains - The active substance is nitric oxide 225 ppm mol/mol, 450 ppm mol/mol or 1000 ppm mol/mol - The other ingredient is nitrogen What Neophyr looks like and contents of the pack Gas cylinders with a capacity of 10l. A 10-liter gas cylinder filled to 150 bar contains about 1,77 kg of gas. Aluminum alloy cylinders have a white painted body and a turquoise-painted shoulder. They are equipped with a stainless steel residual pressure valve with a specific ISO 5145 (2004) type outlet connector.

PIL p. 6/6 Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder SOL S.p.A. Via Borgazzi 27 20900 Monza Italy Manufacturer SOL S.p.A. Via Libertà 247 20900 Monza Italy This medicinal product is authorized in the Member States of the EEA under the following names: Austria: Neophyr Belgium: Neophyr Bulgaria: Neophyr Germany: Neophyr Ireland: Neophyr Italy: Neophyr Luxemburg: Neophyr The Netherlands: Neophyr Romania: Neophyr United Kingdom: Neophyr This leaflet was last revised in 11/2014. The following information is intended for healthcare professionals only. [Full SPC will be included hereafter].